Residual breast cancers after conventional therapy display mesenchymal as tumor-initiating features. There are four (4) files included in this study:
- Sample Annotation (combined_sample_annotation.txt)
- Gene expression data from CD44+/CD24- cells sorted by flow cytometry (GSE7513.gct)
Human breast tumor samples were sorted using flow cytometry to select for cells that were CD44+ and CD24-. Gene expression profiles of these cells were compared with profiles of the other sorted cells (CD24+ and CD44-/CD24-). GEO Accession GSE7513.
- Gene expression data from cancer mammospheres and bulk tumors (GSE7515.gct)
Isolated single cell suspensions from primary breast cancers were plated onto non-adherent (polyhema-coated) plastic, counted with a hematocytometer, and 20,000 cells were then seeded into a 6-well ultra-low attachment plate supplemented with 2mL MEGM, with the addition of 2 mL of freshly unfrozen MEGM every 3-4 days. Gene expression profiles were taken of both MS and primary bulk tumors and compared with each other. GEO Accession: GSE7515
- Letrozole (Femara) early response to treatment (GSE10281.gct)
Biopsies were taken from the same subjects both pretreatment and after 10-14 days Letrozol, 2.5 mg/day, oral. GEO Accession GSE10281
These datasets have been exported from the Broad Institute's ICBP Data & Analysis Portal.
Cite this work
Researchers should cite this work as follows: